Does Bromelain Work? Sinusitis and Surgery vs. the Enzyme-Combo Con

By Erin Rose · Updated July 19, 2026 · Methodology

Educational overview — not medical advice. No finding here should be read as medical guidance for an active illness, infection, or planned surgery. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Four claims, graded on their own evidence — not on each other

Bromelain marketing routinely blends a real post-surgical finding, a thin sinusitis signal, a borrowed-reputation joint-health claim, and a vague "digestive enzyme" pitch into one confident-sounding "natural anti-inflammatory" story. Separated honestly, they're four very different evidence states.

1. Post-surgical (dental) swelling — the strongest thread, with a real null attached

A 2019 systematic review and meta-analysis of 6 RCTs (Liu et al.) after mandibular third-molar extraction found bromelain significantly reduced facial swelling at early (P=.03) and late (P=.0004) timepoints, and pain at the later day-7 timepoint (P=.002). The same meta-analysis found "no apparent effect on early or late trismus." This is the deepest, most consistent evidence bucket in the category — and it is entirely dental-surgery-specific. Full breakdown, including the individual trials and their own limitations, on the post-surgical swelling page.

2. Chronic rhinosinusitis — real mechanism, thin trial base

Bromelain has a genuine biological-plausibility case for sinusitis: a pharmacokinetic study (Passali et al. 2018, n=40) confirmed orally dosed bromelain shows "excellent distribution from blood to rhinosinusal mucosa" — it reaches the target tissue. But that study measured tissue penetration, not symptom relief; it is not a clinical efficacy trial. The only outcome-level data is one small, open-label, uncontrolled pilot (Büttner et al. 2013, n=12, ~3000 FIP/day for 3 months), which reported average improvement in symptom and quality-of-life scores — more effective in patients without nasal polyps than with. No control arm, no blinding, n=12: a real, mechanistically-plausible adjunct signal, not proof of a treatment effect, and it never replaces evaluation for bacterial sinusitis that may need antibiotics or other medical care.

3. Osteoarthritis — bromelain ALONE is weak-to-null; the strong positive trial is a combo

This is where bromelain's marketing most outruns its evidence. The placebo-controlled trial of bromelain ALONE (Brien et al. 2006, n=47 randomized/31 completed, 800mg/day x 12 weeks) tested the primary endpoint of change in total WOMAC score and did NOT meet it (P=0.27) — the authors' own conclusion: bromelain "is not efficacious as an adjunctive treatment of moderate to severe OA." A smaller, single-blind, no-placebo-arm pilot (Kasemsuk et al. 2016, n=40, 500mg/day x 16 weeks) reported within-group WOMAC improvement at week 16 — weaker evidence than Brien's placebo-controlled null, since an unblinded within-group change over 16 weeks doesn't rule out natural fluctuation or expectation effects. The best-designed positive OA trial in this evidence base, Bolten et al. 2015 (n=150, randomized, double-blind, placebo- and diclofenac-controlled), MET its primary Lequesne Functional Index pain endpoint — comparable to diclofenac, both significantly better than placebo (P<0.05), with fewer adverse events than the NSAID (7.2% vs. 15.6%). ⚠️ That trial tested a Wobenzym-type enzyme COMBINATION — bromelain plus trypsin plus rutin — not bromelain alone. Bolten's authors are affiliated with Mucos Pharma and Atrium Innovations, the combination product's manufacturers — disclosed here every time this trial is cited. Give Brien's null primary endpoint equal weight to any positive bromelain-alone OA claim, and never let Bolten's combo result silently back a single-ingredient bromelain product.

4. Digestion and general anti-inflammatory use — the thinnest evidence of the four

Bromelain is a protease, and enzyme physiology supports a plausible digestive role when taken with meals — but this evidence pack found no dedicated human digestion-outcome RCT. The broader "anti-inflammatory" framing rests on mechanism research: a 2001 review (Maurer) documents antiedematous, antithrombotic, and fibrinolytic activity in lab and animal models, and lists traditional/proposed uses spanning sinusitis to bronchitis to enhanced drug absorption. Mechanism research is real research territory, but it is not the same evidence tier as a clinical outcome trial — and this is the thread with the least direct human-outcome data of the four.

Safety, briefly

Generally well tolerated across the trials reviewed; mild GI upset is the most commonly reported adverse effect. Bromelain has a possible antiplatelet/bleeding-potentiation effect — ex vivo human-blood data (Kaur et al. 2016) found it inhibited ADP-induced platelet aggregation and reduced blood coagulability, and it appears on standard herb-warfarin interaction lists (Heck, DeWitt & Lukes 2000), though that review itself cautions the underlying evidence is mostly in vitro, animal, or case-report. Practical guidance: a clinician or pharmacist check for anyone on anticoagulants or antiplatelet medication, and before any planned surgery. Separately, people with known pineapple, papain, or latex allergy are a real cross-reactivity caution group. Pregnancy/breastfeeding: insufficient data exists — an absence-of-data caution, not a specific harm signal.

Compare Bromelain Products

If you're ready to buy, here's how the bromelain products we track and verify compare on cost per 1,000 GDU.

Frequently asked questions

Related

• Bromelain: what it is & who it's for
• Bromelain for post-surgical swelling — the full third-molar-trial breakdown
• Bromelain dosage guide — GDU vs mg, with a dose checker
• Best bromelain — ranked by cost per 1,000 GDU

Sources